Abstract Stress can affect the brain and lead to depression; however, the molecular pathogenesis is unclear. An association between stress and stress-induced hypersecretion of glucocorticoids occurs during stress. Dexamethasone (a synthetic glucocorticoid steroid) has been reported to induce apoptosis and increase the activity of monoamine oxidase (MAO) (Youdim et al. 1989) . MAO is an enzyme for the degradation of aminergic neurotransmitters; dopamine, noradrenaline and serotonin and dietary amines and MAO inhibitors are classical antidepressant drugs. In this study, we have compared the ability of rasagiline (Azilect) and its main metabolite, R-aminoindan with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death employing human neuroblastoma SH-SY5Y cells and glioblastoma 1242-MG cells. Dexamethasone reduced cell viability as measured by MTT test, but rasagiline, selegiline, and 1-R-aminoindan could significantly prevent dexamethasone-induced brain cell death. Among three drugs, rasagiline had the highest neuroprotective effect. Furthermore, the inhibitory effects of these drugs on MAO B catalytic activity and on apoptotic DNA damage (TUNEL staining) were examined. Rasagiline exhibited highest inhibition on MAO B enzymatic activity and prevention on DNA damage as compared to selegiline and 1-R-aminoindan. In summary, the greater neuroprotective effect of rasagiline may be associated with the combination of the parent drug and its metabolite 1-R-aminoindan.
Introduction
The brain is the key organ in the response to stress. Longterm stressful situations can affect the brain and lead to depression. For example, environmental stressors related to job or family situations are important triggers of depressive episodes. Major depression is one of the world's greatest public health burdens. However, the development of novel antidepressants is based upon an improved neurobiological understanding on the cellular changes that take place in the brain during the long-term stress. The major hormonal response to stress is in the form of glucocorticoids. Glucocorticoids are the steroid hormones secreted from adrenal gland during stress. Abnormal increased levels of glucocorticoids are associated with atrophy in the hippocampus (Lee et al. 2002 ) and also associated with major depression (Duval et al. 2006 ). Thus, glucocorticoids may play a contributing role toward neuronal death and depression. Anti-glucocorticoid drugs appear to be an effective therapy for anti-depression (Murphy 1997) . Steroid hormones are involved in the regulation of many functions in which monoamine oxidase (MAO) also plays important roles such as response to stress, behavioral adaptation, and mood (de Kloet et al. 1990) . MAO is an enzyme located on the outer membrane of the mitochondria. The synthetic glucocorticoid, dexamethasone, increases MAO A activity in the human neuroblastoma (Ou et al. 2006a) , the human fibroblasts (Edelstein and Breakefield 1986) , and rat brain frontal cortex (Slotkin et al. 1998 ). Both anti-glucocorticoid agents (Wolkowitz and Reus 1999) and MAO A inhibitors (Kato et al. 1998; Volz and Gleiter 1998) have been used in the treatment of depression.
MAO exists in two isoforms, MAO A and MAO B (Shih et al. 1999) . However, within the human brain, MAO B is much more prevalent in the striatum. MAO B catalyzes biogenic and dietary amines including neurotransmitters (such as phenylethylamine and dopamine), and produces hydrogen peroxide (H 2 O 2 ), a toxic product that induces cell apoptosis (Ou et al. 2006b; Johnson et al. 2007) .
Apoptosis can be prevented with the use of propargylamine-derived MAO B inhibitors (Malorni et al. 1998; Youdim et al. 2001b; Youdim et al. 2005b ). Two such inhibitors, rasagiline (Azilect) and selegiline (1-Deprenyl or Emsam), were developed in the treatment of Parkinson's disease. Both of these drugs are irreversible inhibitors of MAO B, where rasagiline is a restricted analog of selegiline. Rasagiline is significantly more active in vivo than selegiline (Youdim et al. 2001a) . They differ, however, by their metabolic products. Whereas selegiline (1-Deprenyl) is metabolized to amphetaminic metabolites, rasagiline is metabolized to neuroprotective aminoindan. L-methampehtamine, the metabolite of selegiline, produces neurotoxic effects that may counterbalance the neuroprotective effects of selegiline. On the other hand, aminoindan has no neurotoxic effects and has also been shown to have its own neuroprotective activity (Youdim et al. 2001a; BarAm et al. 2007 ). Dexamethasone also has been shown to induce apoptosis at concentrations of 100 nM-100 lM (Glick et al. 2000; Dolmatov et al. 2004; Jacobs et al. 2006) . In this study, we have employed dexamethasone (10 lM) to induce apoptosis in order to evaluate the neuroprotective properties of rasagiline, selegiline (deprenyl), and rasagiline's major metabolite, 1-R-aminoindan, in protection against cell death-induced by toxicity of dexamethasone.
Materials and Methods

Cell Lines and Reagents
A human neuroblastoma SH-SY5Y cell line was used. This line was purchased from ATCC. The cells were grown and cultured in RPMI 1640 media and supplemented with 10% fetal bovine serum, and a human glioblastoma 1242-MG cell line was also used. It was obtained as a gift from Dr. B. Westermark (Dept. of Pathology, University Hospital, Uppsala, Sweden). They were grown and cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum. Rasagiline was synthesized by a Ph.D student, Hailin Zheng, in the laboratory of Dr. Youdim's (Haifa, Israel) . 1-R-aminoindan and selegiline (deprenyl) were purchased from Sigma-Aldrich USA. In Situ Cell Death Detection Kit (for TUNEL staining) was purchased from Roche (Indianapolis, IN).
Cell Culture and Treatments
The SH-SY5Y and 1242-MG cells were seeded into 6-well plates and cultured overnight in medium. Cells were supplemented with charcoal-stripped, steroid-free fetal calf serum for *6 h. The medium was then replaced with medium treated with 10 lM of dexamethasone, 0.25 nM of rasagiline, 0.25 nM of selegiline, or 1 lM of 1-R-aminoindan in the presence of charcoal-stripped fetal calf serum. The treatments were performed every other day for 4 days.
MAO B Catalytic Activity Assay
SH-SY5Y and 1242-MG cells were grown to confluence, harvested, and washed with phosphate-buffered saline. One hundred micrograms of total proteins were incubated with 10 lM 14 C-labeled phenylethylamine (Amersham Biosciences) in the assay buffer (50 mM sodium phosphate buffer, pH 7.4) at 37°C for 20 min and terminated by the addition of 100 ll of 6 N HCl. The reaction products were then extracted with ethyl acetate/toluene (1:1) and centrifuged at 4°C for 10 min. The organic phase containing the reaction product was extracted, and its radioactivity was obtained by liquid scintillation spectroscopy (Geha et al. 2001) .
MTT Assay
The survival and proliferation of the cells were measured using MTT assays. MTT, (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetrazolium bromide), is a yellow tetrazolium salt that is metabolized within the cell to form a purple formazan crystal, which can then be dissolved using a detergent in order to measure the solution's light absorbance. First, the MTT solution (5 mg/ml) was diluted with PBS to form a 19 solution (0.5 mg/ml). For the 6-well plates, 400 ll of MTT dye was added to each well. Then, the cells were left to incubate for 4-5 h. During this incubation period, the yellow dye was converted by the mitochondria of the viable cells into a purple formazan crystal, which were then dissolved by 1.2 ml of DMSO. The NanoDrop Spectrophotometer was used to determine the optical density at 572 nm of each well.
TUNEL Assay
The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP Nick End Labeling (TUNEL) assay was used to assess the extent of apoptosis in treated cells. Briefly, cells were plated on a four-well chamber slide on the day preceding the experiment, and treated with or without 10 lM dexamethasone, 0.25 nM of rasagiline, 0.25 nM of selegiline, or 1 lM of 1-R-aminoindan for 2 days. Cells were then washed with PBS and fixed using 4% paraformaldehyde in PBS. The slides were again washed with PBS, and fragmented DNA was detected in apoptotic cells by adding fluorescein 12-dUTP to nicked ends of DNA (In Situ Cell Death Detection Kit, Roche). Slides were incubated for 1 h at 37°C in the dark and washed in PBS three times and then visualized with a fluorescent light microscope. Green fluorescence was correlated with DNA fragmentation. Experiments were done in duplicate for three times, and the percentage of TUNEL-positive cells was determined.
Statistical Analysis
The statistical significance was evaluated using one-way ANOVA to test for differences between groups and followed by post-hoc t-tests. A value of P \ 0.05 was considered to be significant.
Results
The expression of MAO B was investigated in two human brain cell lines, neuroblastoma SH-SY5Y, and glioblastoma 1242-MG. Cells were seeded in 10-cm dishes. After 24 h, cells were treated with dexamethasone (0 or 10 lM) and/or 0.25 nM rasagiline or selegiline or 1 lM 1-R-aminoindan for 96 h. The MAO B catalytic activities were determined (Fig. 1A, B) . The results indicated MAO B enzymatic activity was significantly increased with the dexamethasone treatment in both cell lines, confirming previous studies in endothelial and chromaffin cells (Youdim et al. 1989 ). In Fig. 1A (lanes 3 vs. 1 and 4 vs. 2), MAO B catalytic activity significantly increases by twofold after treatment with dexmethasone in both SH-SY5Y and 1242-MG (P \ 0.02). In Fig. 1B , rasagiline lowers MAO B catalytic activity by *70% in SH-SY5Y (Fig. 1B , lane 2 vs. 1) and *60% 1242-MG (Fig. 1B , lane 6 vs. 5)-more significantly in SH-SY5Y (P \ 0.02). Selegiline and 1-R-aminoindan also significantly (P \ 0.05) lower the catalytic activity of MAO B by about 50% in both SH-SY5Y and 1242-MG cells (Fig. 1B, lanes 3 vs. 1, 4 vs. 1, 7 vs. 5, and 8 vs. 5, respectively).
Furthermore, the evaluation of cell viability was performed by determining cell proliferation rates among the different treatment groups with MTT Assay (Fig. 2A, B) . The results indicated that the proliferation of SH-SY5Y and 1242-MG significantly (P \ 0.05) decreased with the Fig. 1 Effects of dexamethasone and MAO B inhibitors on MAO B catalytic activity. A. Dexamethasone increases the MAO B catalytic activity in both SH-SY5Y and 1242-MG. Cells were treated with dexamethasone (0 or 10 lM) for 96 h, and the MAO B catalytic activities were determined. *P \ 0.02 compared with control cells (without treatment). B. The MAO B inhibitors, rasagiline, selegiline, and 1-R-aminoidan (rasagiline's metabolite) decrease MAO B catalytic activity induced by dexamethasone in both SH-SY5Y and 1242-MG. Cells were treated with dexamethasone (0 or 10 lM) and/ or 0.25 nM rasagiline or selegiline or 1 lM 1-R-aminoindan for 96 h, and the MAO B catalytic activities were determined. *P \ 0.02 and **P \ 0.01 compared to cells treated with dexamethasone alone addition of 10 lM Dexamethasone ( Fig. 2A, lanes 3 vs. 1 and 4 vs. 2, respectively). The survival rate of SH-SH5Y is decreased by *35%; subsequently, the proliferation rate of 1242-MG is decreased by *32% after dexamethasone treatment. Whereas, the addition of rasagiline, selegiline, and 1-R-aminoindan significantly increased the proliferation rates of SH-SY5Y and 1242-MG upon dexamethasone treatment. Rasagiline had the greatest effect on both SH-SY5Y and 1242-MG (Fig. 2B , lanes 2 vs. 1 and 6 vs. 5, respectively). Rasagiline caused *60% increase in the cell proliferation rate for SH-SY5Y cells treated with dexamethasone. Selegiline and 1-R-aminoidan cause *25% increase in the proliferation of SH-SY5Y cells treated with dexamethasone (Fig. 2B, lanes 3 vs. 1 and 4 vs. 1, respectively). In 1242-MG, rasagiline causes *35% increase in cell proliferation rates (Fig. 2B , lanes 6 vs. 5) while both selegiline and 1-R-aminoidan cause *20% increase (Fig. 2B , lanes 7 vs. 5 and 8 vs. 5, respectively) in viability of dexamethasone-treated cells.
Results from the MAO B activity assay ( Fig. 1A and B) and MTT assay ( Fig. 2A and B) were further supported by the TUNEL assay (Fig. 3) , since an increase in MAO B catalytic activity may produce more H 2 O 2 . H 2 O 2 can cause cell apoptosis which can be detected by measuring fragmented DNA using TUNEL staining (Phillips et al. 2003) . As shown in Fig. 3A , green fluorescent-labeled DNA fragmentation in SH-SY5Y after treatment with dexamethasone significantly increased compared to untreated cells (Fig. 3A, 2 vs. 1) . Additionally, Fig. 3 also indicates that treatment with rasagiline, selegiline, or 1-R-aminoidan significantly decreased the percentage of TUNEL-positive cells present in the dexamethasone-treated group (Fig. 3A,   3 vs. 2). Rasagiline causes a 30% decrease in fragmented DNA of dexamethasone-treated SH-SY5Y cells (P \ 0.02; Fig. 3B , lanes 6 vs. 5). Selegiline and 1-R-aminoidan cause a 20% decrease in the amount of fragmented DNA present in SH-SY5Y cells treated with dexamethasone (P \ 0.05; Fig. 3B , lanes 7 vs. 5 and 8 vs. 5, respectively). Similar results were exhibited by 1242-MG cells (data not shown).
Discussion
The results of this study indicated that dexamethasone reduces cell proliferation rates but increases MAO B catalytic activity. The aberrant increase of MAO B activity has been implicated in neurodegenerative diseases, such as Alzheimer's disease (Saura et al. 1994 ), Parkinson's disease (Schneider et al. 1981 ), Huntington's disease (Mann et al. 1986; Senatorov et al. 2003) , and alcoholism (Carlsson et al. 1980) . Dexamethasone has been reported to induce MAO B expression and activity in endothelial and astrocytes in a dose-and time-dependent manner (Carlo et al. 1996) . The abnormally increased MAO B catalytic activity may produce toxic products, such as H 2 O 2 , therefore these data support an important role for glucocorticoids in the increase in brain MAO B associated with neurodegenerative diseases and mental disorders. In contrast, the MAO B inhibitors, deprenyl (selegiline) and Azilect Ò (rasagiline), have been used in the therapy of neurodegenerative diseases such as Parkinson's Disease (Paterson et al. 1997; Tatton et al. 2000; Maruyama et al. 2001; Fernandez and Chen 2007) , depression (Goodnick 2007; Robinson and Amsterdam 2007) , and senile Fig. 2 Effects of dexamethasone and MAO B inhibitors on cell proliferation rates. A. Dexamethasone lowers the proliferation rates of both SH-SY5Y and 1242-MG cells. Cells were treated with dexamethasone (0 or 10 lM) for 96 h, and the proliferation rates were determined by MTT assay. *P \ 0.05 compared with control cells (without treatment). B. The MAO B inhibitors, rasagiline, selegiline, and 1-R-aminoidan (rasagiline's metabolite) increase the proliferation rates in both SH-SY5Y and 1242-MG. Cells were treated with dexamethasone (0 or 10 lM) and/or 0.25 nM rasagiline or selegiline or 1 lM 1-R-aminoindan for 96 h, and the proliferation rates were determined by MTT assay. *P \ 0.05 and **P \ 0.02 compared to cells treated with dexamethasone alone Neurotox Res (2009) 15:284-290 287 dementia (Tariot et al. 1987; Youdim et al. 2005a; Youdim 2006) . However, whether these drugs can also protect neurons from glucocorticoids-induced toxicity has never been studied. We report here for the first time that rasagiline, selegiline, and 1-R-aminoindan significantly prevent dexamethasoneinduced brain cell death involving in both neuroblastoma and glioblastoma cells. Among the three compounds, rasagiline has the highest neuroprotective effect compared to either selegiline or 1-R-aminoindan. Rasagiline (Azilect) and selegiline (1-deprenyl or Emsam) are irreversible inhibitors of MAO B. The greater neuroprotective quality of rasagiline may in part be due to the effects of the parent compound and its major metabolite, 1-R-aminoindan. Furthermore, the inhibitory effects of these drugs on MAO B catalytic activity and on apoptotic DNA fragment damage (observed by TUNEL staining) were examined. Rasagiline has shown the highest inhibition on MAO B enzymatic activity (Youdim et al. 2001a ) and also has shown the highest prevention on apoptosis compared to selegiline and 1-R-aminoindan. The mechanism by which rasagiline and selegiline initiate their anti-apoptotic effect can be summarized by their up regulation of anti-apoptotic Bcl-2 and BclXl and down regulation of propaoptotic Bad, Bax, PARP, and caspase 3 (see Youdim et al. 2005a ) and Youdim et al. 2006 ) for reviews). Because Bcl-2 and caspase 3 are key factors for preventing or mediating the mitochondrialinvolved apoptosis (Lakhani et al. 2006) , it suggests that the MAO inhibitors may protect cells from apoptosis through a mechanism involving the maintenance of mitochondrial homeostasis (Malorni et al. 1998 ). In addition, structure activity studies with rasagiline have shown that it is propargylamine moiety that produces this effect, since propargylamine which has little or no MAO inhibitory activity has a similar mechanism of neuroprotective activity with similar potency . Furthermore, both rasagiline and proppargylamine activate neuroprotective protein kinase C (PKCa and PKCe), while downregulating propaoptotic PKCd and c. Inhibition of PKC by GF109203X prevents their neuroprotective activity Youdim et al. 2005a) . The mechanism by which aminoindan has been fully elucidated. The neuroprotective properties of 1-R-aminoindan have been assessed employing a cytotoxic model of human neuroblastoma SK-N-SH cells in high-density culture-induced neuronal death and in response to 6-hydroxydopamine. We show that 1-Raminoindan (0.1-1 lM) significantly reduced the apoptosisassociated phosphorylated protein, H2A.X (Ser139), decreased the cleavage of caspase 9 and caspase 3, while increasing the anti-apoptotic proteins, Bcl-2 and Bcl-xl. Protein kinase C (PKC) inhibitor, GF109203X, prevented the neuroprotection, indicating the involvement of PKC in aminoindan-induced cell survival. Aminoindan markedly elevated pPKC (pan) and specifically that of the pro-survival PKC isoform, PKC epsilon (Bar-Am et al. 2007) .
In summary, the neurorptoective activity seen with rasagiline and its major metabolite, 1-R-aminoindan in the present and previous studies, may have relevance to the recent prospective clinical study in Parkinsonian subjects, ADAGIO, where rasagiline indicated that early treatment with rasagiline provided benefits that were not obtained with later initiation of the drug. This is the first time that a prospective large-scale, randomized, double-blind trial has provided evidence that a drug might slow down PD progression via neuroprotection (Hughes 2008) . 
